Viridian Therapeutics, Inc.\DE
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
VRDN$30.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Year EndedDecember 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenues: | |||
| License revenue | $70,000 | $— | $— |
| Collaboration revenue - related parties | 849 | 302 | 314 |
| Total revenues | 70,849 | 302 | 314 |
| Operating expenses: | |||
| Research and development | 338,929 | 238,254 | 159,765 |
| Selling, general and administrative | 95,315 | 61,083 | 94,999 |
| Total operating expenses | 434,244 | 299,337 | 254,764 |
| Loss from operations | (363,395) | (299,035) | (254,450) |
| Other income (expense), net: | |||
| Interest income | 27,399 | 31,597 | 18,240 |
| Interest expense | (4,948) | (2,197) | (1,331) |
| Other expense, net | (1,657) | (314) | (193) |
| Total other income, net | 20,794 | 29,086 | 16,716 |
| Net loss | $(342,601) | $(269,949) | $(237,734) |
| Net loss per share, basic and diluted, common stock | $(3.32) | $(3.07) | $(3.91) |
| Weighted-average shares common shares outstanding, basic and diluted | 84,803,355 | 67,885,831 | 44,755,475 |
| Net loss per share, basic and diluted, Series A convertible preferred stock | $(221.65) | $(204.82) | $(260.70) |
| Weighted-average Series A convertible preferred shares outstanding, basic and diluted | 134,864 | 154,856 | 174,226 |
| Net loss per share, basic and diluted, Series B convertible preferred stock | $(221.65) | $(204.82) | $(260.69) |
| Weighted-average Series B convertible preferred shares outstanding, basic and diluted | 138,875 | 144,862 | 66,385 |
| Comprehensive loss: | |||
| Net loss | $(342,601) | $(269,949) | $(237,734) |
| Other comprehensive income (loss): | |||
| Unrealized gain (loss) on available-for-sale securities | 457 | (348) | 728 |
| Total other comprehensive income (loss) | 457 | (348) | 728 |
| Comprehensive loss | $(342,144) | $(270,297) | $(237,006) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.